SCHEMBL6441743

SCHEMBL6441743

CCCCOc1nc(N)nc(-c2ccco2)c1C#N

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 7/20 0.56
ADORA2A P29274 7/20 0.56
ADORA2B P29275 3/20 0.56
HPGD P15428 6/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
KDM4E B2RXH2 8/20 0.47
NPSR1 Q6W5P4 2/20 0.47
ALDH1A1 P00352 7/20 0.44
HSD17B10 Q99714 6/20 0.44
MEN1 O00255 5/20 0.44
KMT2A Q03164 5/20 0.44
TSHR P16473 2/20 0.44
POLB P06746 3/20 0.44
LMNA P02545 1/20 0.43
MAPT P10636 4/20 0.43
NPC1 O15118 1/20 0.43
TP53 P04637 1/20 0.43
RAB9A P51151 1/20 0.43
MAPK8 P45983 1/20 0.42
MAPK9 P45984 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5046844 0.89 ADORA1 (0.60) ADORA1ADORA2AADORA2BHPGDSMN1; SMN2
SCHEMBL6440638 0.88 ADORA2A (0.56) ADORA1ADORA2AADORA2BHPGDKDM4E
SCHEMBL6449356 0.86 ADORA2A (0.54) ADORA1ADORA2AADORA2BHPGDSMN1; SMN2
SCHEMBL5036930 0.85 ADORA2A (0.59) ADORA1ADORA2AADORA2BHPGDKDM4E
SCHEMBL6441085 0.84 ADORA2A (0.58) ADORA1ADORA2AADORA2BHPGDKDM4E
SCHEMBL5037058 0.84 ADORA2A (0.60) ADORA1ADORA2AADORA2BHPGDKDM4E
SCHEMBL6443406 0.83 ADORA2A (0.64) ADORA1ADORA2AADORA2BHPGDKDM4E
SCHEMBL7147864 0.82 KDM4E (0.45) ADORA1ADORA2AHPGDSMN1; SMN2KDM4E
SCHEMBL5036966 0.81 ADORA2A (0.57) ADORA1ADORA2AADORA2BHPGDKDM4E
SCHEMBL7889106 0.81 ADORA2A (0.57) ADORA1ADORA2AADORA2BHPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP disclosed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 ADORA1 3/4885ADORA2A 1/4885ADORA2B 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.